Emcure Pharmaceuticals Limited
Incorporated in 1981, Emcure Pharmaceuticals Limited is an Indian company that develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.
What Emcure files
- Others61
- Investor Meet33
- Updates23
- Important22
- Board Meeting10
- JV/Acquisition9
Emcure's subsidiary, Gennova, sold its mRNA business for 139.5 Cr cash via slump sale to Immunoscript Life Science. This strategic move helps Gennova focus on core biotech products and biosimilars. The divested mRNA unit contributed 64.71 Cr revenue and 132.63 Cr net worth in FY26.
Emcure Pharmaceuticals reported a fire at its Hinjawadi plant's utility block, causing a temporary 5-7 day operational disruption. No injuries occurred. The plant is fully insured, and the company anticipates no material financial impact.
Emcure Pharmaceuticals received approval from stock exchanges for reclassifying several Promoter Group members as Public shareholders. These individuals/entities, who previously held NIL percent shareholding, are now designated public shareholders.
Emcure Pharmaceuticals announces 15 members of its Promoter and Promoter Group have withdrawn their request to be re-classified as 'Public' shareholders. They will continue their status within the Promoter Group, ensuring stability in key shareholding.
Emcure Pharmaceuticals has updated the email address for its Registrar and Share Transfer Agent (RTA). Investors should now use 'Investor.helpdesk@in.mpms.mufg.com' for all RTA-related inquiries; other contact details are unchanged.